The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells

International Journal of Gynecological Cancer

Volumn 23, Issue 1, 2013, Pages 52-59

  Ge, Xin ^a   Guo, Ruixia ^a   Qiao, Yuhuan ^a   Zhang, Yancai ^a   Lei, Jia ^a   Wang, Xinyan ^a   Li, Liuxia ^a   Hu, Dongmei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Endometrial cancer; Estrogen; GPR30; PI3K Akt pathway

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30;

ARTICLE; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VIVO STUDY; ISHIKAWA CELL; LONG TERM CARE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; CYTOPLASM; ENDOMETRIAL NEOPLASMS; ENZYME ACTIVATION; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872316930     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31827912b8     Document Type: Article

References (23)

1. Guo R-X, Wei L-H, Tu Z, et al. 17β-Estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)Ydependent and ER-independent mechanisms in endometrial cancer cells. J Steroid Biochem Mol Biol. 2006;99:9-18.
2. Ruan S-Q, Wang Z-H, Wang S-W, et al. Heregulin-b1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway. Biochem Biophys Res Commun. 2012;420:385-490.
3. Du G-Q, Zhou L, Chen X-Y, et al. The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells. Biochem Biophys Res Commun. 2012;420:343-349.
4. Revankar CM, Cimino DF, Sklar LA, et al. A transmembrane intracellular estrogen receptor mediates rapid cell signalling. Science. 2005;307:1625-1630.
5. Honda K, Sawada H, Kihara T, et al. Phosphatidylinositol 3-kinase mediates neuroprotection by estrogen in cultured cortical neurons. J Neurosci Res. 2000;60:321-327.
6. Ivanova T, Mendez P, Garcia-Segura LM, et al. Rapid stimulation of PI-3kinase/Akt signaling pathway in developing midbrain neurons by oestrogen. J Neuroendocrinol. 2002;14:73-79.
7. Filardo EJ, Thomas P. G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology. Endocrinology. 2012;153:2953-2962.
8. Guzeloglu Kayisli UA, Luleci G, Arici A. In vivo and in vitro regulation of Akt activation in human endometrial cells is estrogen dependent. Biol Reprod. 2004;71:714-721.
9. Lin BC, Suzawa M, Blind RD, et al. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res. 2009;69:5415-5423.
10. Plante BJ, Lessey BA, Taylor RN, et al. G protein-coupled estrogen receptor (GPER) expression in normal and abnormal endometrium. Reprod Sci. 2012;19:684-693.
11. Levin ER. G protein-coupled receptor 30: estrogen receptor or collaborator? Endocrinology. 2009;150:1563-1565.
12. Lubig J, Lattrich C, Springwald A, et al. Effects of a combined treatment with GPR30 agonist G-1 and herceptin on growth and gene expression of human breast cancer cell lines. Cancer Invest. 2012;30:372-379.
13. Bologa CG, Revankar CM, Young SM, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006;4:207-212.
14. Nishida M. The Ishikawa cells from birth to the present. Hum Cell. 2002;15:104-117.
15. Stoner M, Wang F, Wormke M, et al. Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 protein. J Biol Chem. 2000;275:22769-22779.
16. Vivacqua A, Bonofiglio D, Recchia AG, et al. The G Protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells molecular. Endocrinology. 2006;20:631-646.
17. Bryant W, Snowhite AE, Rice LW, et al. The estrogen receptor (ER)α variant delta5 exhibits dominant positive activity on ER-regulated promoters in endometrial carcinoma cells. Endocrinology. 2005;146:751-759.
18. Klinge CM, Jernigan SC, Risinger KE. The agonist activity of tamoxifen is inhibited by the short heterodimer partner orphan nuclear receptor in human endometrial cancer cells. Endocrinology. 2002;143:853-867.
19. Hall JM, Course JF, Korach KS. The multifaceted mechanism of estradiol and estrogen receptor signalling. J Biol Chem. 2001;276:36869-36872.
20. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol. 2005;19:1951-1959.
21. Albanito L, Madeo A, Lappano R, et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17B-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 2007;67:1859-1866.
22. Thornton JW, Need E, Crews D. Resurrecting the ancestral steroid receptor: ancient origin of estrogen signaling. Science. 2003;301:1714-1717.
23. He Y-Y, Cai B, Yang Y-X, et al. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Science. 2009;100:1051-1061.